New malaria combo shows promise for kids in phase 2 trial

NCT ID NCT04546633

First seen May 15, 2026 · Last updated May 15, 2026

Summary

This study tested a new combination of two drugs, KAF156 and lumefantrine, in 295 children aged 6 months to 18 years with uncomplicated malaria. The goal was to see if the treatment works well and is safe. The approach aims to provide a new option to fight malaria and reduce the chance of drug resistance.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UNCOMPLICATED PLASMODIUM FALCIPARUM MALARIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Novartis Investigative Site

    Banfora, Burkina Faso

  • Novartis Investigative Site

    Bobo-Dioulasso, 01, Burkina Faso

  • Novartis Investigative Site

    Ouagadougou, Burkina Faso

  • Novartis Investigative Site

    Sabou, 06 BP 10248, Burkina Faso

  • Novartis Investigative Site

    Abidjan, 13BP972, Côte d’Ivoire

  • Novartis Investigative Site

    Lambaréné, BP 242, Gabon

  • Novartis Investigative Site

    Kati, Mali

  • Novartis Investigative Site

    Sotouba, Mali

  • Novartis Investigative Site

    Lubumbashi, Du Haut Katanga, 7010, Republic of the Congo

Conditions

Explore the condition pages connected to this study.